Global News

CRISPR, Intellia, Caribou and ERS Genomics provide update on CRISPR/Cas9 U.S. patent

Friday, February 17, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics provided an update on the Patent Trial & Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) decision on the motions filed by the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively, UC), on one hand, and the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively, Broad), on the other, in the interference proceeding relating to CRISPR/Cas9 genome editing technology.

[Read More]

Integra LifeSciences to acquire the Codman Neurosurgery Business for $1.04B in Cash

Thursday, February 16, 2017

Integra LifeSciences, a global provider of medical technology, has made a binding offer to acquire the Johnson & Johnson Codman Neurosurgery business for a price of $1.045 billion in cash. Codman Neurosurgery offers a portfolio of devices focused on advanced hydrocephalus, neuro-critical care and operative neurosurgery. If the binding offer is accepted, upon closing, Integra will be a global provider of neurosurgical products.

[Read More]

Ardelyx announces successful phase III trial of tenapanor for hyperphosphatemia

Thursday, February 16, 2017

Ardelyx, a clinical-stage company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, has reported that the phase III clinical trial evaluating the efficacy and safety of tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis met its primary endpoint and was generally well-tolerated.

[Read More]

Gilead releases Genvoya HIV-1 data

Thursday, February 16, 2017

Gilead Sciences announced 144-week data from two phase III studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya (elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and tenofovir alafenamide 10mg) for the treatment of HIV-1 infection in treatment-naïve adults. Through week 144, Genvoya demonstrated significantly higher rates of virologic suppression compared to Gilead’s Stribild (elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and tenofovir disoproxil fumarate 300mg), based on the%age of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also demonstrated favorable renal and bone laboratory parameters compared to those treated with Stribild.

[Read More]

Certara Vice President Piet van der Graaf appointed F1000Prime faculty member

Thursday, February 16, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that Professor Piet van der Graaf, PharmD, Ph.D., its vice president of quantitative systems pharmacology, has been appointed an F1000Prime faculty member. In this new role, Professor van der Graaf will contribute article reviews and recommendations to the Systems & Network Biology Section of the Bioinformatics, Biomedical Informatics & Computational Biology Faculty. He will be responsible for summarizing each article, explaining its value, and adding a rating score.

[Read More]

ERT named finalist for PACT Technology Company of the Year award

Thursday, February 16, 2017

ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, has been named a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) Technology Company of the Year award. ERT is one of only three companies nominated to receive this recognition.

[Read More]